This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04248829
Recruitment Status : Active, not recruiting
First Posted : January 30, 2020
Last Update Posted : September 6, 2023
Information provided by (Responsible Party):
Yuhan Corporation

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 29, 2022
Estimated Study Completion Date : June 2024
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 February 16, 2024